Dexcom announces direct-to-watch feature for G7 CGM
Mar 5, 2024 · The ONE+ system, featuring a sensor, reader, smartphone, smartwatch and applicator. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year.
Insulet data shows Omnipod 5's superiority to regular pump therapy
Mar 8, 2024 · The Omnipod 5 with the Abbott FreeStyle Libre 2 Plus. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against non-automated insulin therapy. Acton, Massachusetts-based Insulet conducted its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 ...
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S.
Jun 20, 2024 · The Omnipod 5 with the Dexcom G7 CGM. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) announced today that it began a full U.S. launch of Omnipod 5 with the Dexcom G7 continuous glucose monitor (CGM). The company also announced a series of launches and updates, including a limited release of the Omnipod 5 App for iPhone.
Dexcom to update G7, delaying FDA clearance, launch timelines
Jul 28, 2022 · [Image from Dexcom] The CEO of Dexcom (Nasdaq:DXCM) said today that the company’s regulatory path for the next-generation G7 has been slightly delayed. Speaking on the continuous glucose monitor (CGM) maker’s second-quarter earnings call, Dexcom Chair, President and CEO Kevin Sayer explained that the company has — based on feedback from the FDA — been tweaking the software of its next ...
Insulet progresses on Omnipod 5, FreeStyle Libre 2 integration
Jun 22, 2023 · The Insulet Omnipod 5 [Photo courtesy of Insulet] Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development. Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83 rd Scientific Sessions in San Diego.
The 9 largest diabetes technology companies in the world
Aug 21, 2024 · Technologies from Abbott, Dexcom, Medtronic and Insulet. These companies are the four largest diabetes technology companies in the world. [Images courtesy of the companies] Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in …
Medicare to cover Dexcom G7 when it launches this week
Feb 13, 2023 · The G7 product family. [Image from Dexcom] Dexcom (Nasdaq:DXCM) announced today that Medicare offers coverage for its beneficiaries using the next-generation G7 CGM. The company announced the coming U.S. launch for G7 in a Super Bowl Commercial with musician Nick Jonas last night. It’s slated to roll out on Friday, Feb. 17. San Diego-based Dexcom met the category requirements for therapeutic ...
Dexcom launches Stelo over-the-counter CGM - Drug Delivery …
Aug 26, 2024 · A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it launched its Stelo over-the-counter (OTC) continuous glucose monitor (CGM) biosensor. The San Diego-based company made Stelo available for purchase — without prescription — at Stelo.com. Dexcom became the first company to receive FDA clearance for an OTC CGM ...
FDA approves next-gen drug delivery system from Medtronic
Oct 10, 2023 · The SynchroMed III system. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system. The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity.
Dexcom CEO explains plans for Stelo CGM, G7 and beyond
Jun 23, 2024 · The Stelo glucose monitor. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) CEO Kevin Sayer says the prospect of an over-the-counter CGM made him and other company leaders uneasy. When the company first began planning a glucose monitor for the type 2 diabetes population not using insulin, there were questions about reimbursement, the impact of GLP-1 drugs and other causes for concern.